down arrow

Theriva Biologics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87164U4094
USD
0.24
0.04 (20.74%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.200.25

52 Week

0.202.08
Valuation
Technical
Day's Volume

CASH

6.84 M

Shareholding (Jun 2025)

FII

0.64%

Held by 5 FIIs

DII

98.34%

Held by 1 DIIs

Promoter

0.00%

How big is Theriva Biologics, Inc.?

22-Jun-2025

As of Jun 18, Theriva Biologics, Inc. has a market capitalization of 3.82 million and reported net sales of 0.00 million with a net profit of -24.82 million over the latest four quarters. Shareholder's funds are at 19.07 million, and total assets are 39.74 million.

As of Jun 18, Theriva Biologics, Inc. has a market capitalization of 3.82 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -24.82 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 19.07 million and Total Assets at 39.74 million.

Read More

What does Theriva Biologics, Inc. do?

22-Jun-2025

Theriva Biologics, Inc. is a clinical-stage company focused on developing therapeutics for gastrointestinal diseases, classified as a micro-cap with a market cap of $3.82 million. As of March 2025, it reported a net profit loss of $4 million and has no dividend yield.

Overview: <BR>Theriva Biologics, Inc. is a clinical-stage company engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3.82 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.51 <BR>Return on Equity: -114.14% <BR>Price to Book: 0.25<BR><BR>Contact Details: <BR>Address: 9605 Medical Center Dr Ste 270, ROCKVILLE MD: 20850-6382 <BR>Tel: 1 734 3327800 <BR>Fax: 1 734 3327878 <BR>Website: https://www.syntheticbiologics.com/

Read More

Who are in the management team of Theriva Biologics, Inc.?

22-Jun-2025

As of March 2022, the management team of Theriva Biologics, Inc. includes Mr. Jeffrey Kraws (Non-Executive Independent Chairman), Mr. Steven Shallcross (CEO, CFO, Director), Dr. John Monahan (Director), and Mr. Jeffrey Wolf (Independent Director).

As of March 2022, the management team of Theriva Biologics, Inc. includes the following individuals:<BR><BR>- Mr. Jeffrey Kraws, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Mr. Steven Shallcross, who holds the positions of Chief Executive Officer, Chief Financial Officer, and Director.<BR>- Dr. John Monahan, who is a Director.<BR>- Mr. Jeffrey Wolf, who is an Independent Director.

Read More

Is Theriva Biologics, Inc. technically bullish or bearish?

20-Sep-2025

As of June 5, 2025, Theriva Biologics, Inc. shows a mildly bearish trend with conflicting indicators, including a bearish daily moving average and weekly Bollinger Bands, but mildly bullish signals from the MACD and KST, while significantly underperforming the S&P 500 with a year-to-date return of -76.39%.

As of 5 June 2025, the technical trend for Theriva Biologics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish daily moving average and bearish signals from the weekly Bollinger Bands. However, there are mildly bullish indicators on the weekly MACD and KST, along with a bullish monthly RSI and OBV. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -76.39% versus the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.92

stock-summary
Return on Equity

-163.29%

stock-summary
Price to Book

0.35

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-38.08%
0%
-38.08%
6 Months
-47.25%
0%
-47.25%
1 Year
-81.97%
0%
-81.97%
2 Years
-98.4%
0%
-98.4%
3 Years
-66.44%
0%
-66.44%
4 Years
-99.69%
0%
-99.69%
5 Years
-99.74%
0%
-99.74%

Theriva Biologics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Theriva Biologics, Inc. technically bullish or bearish?

As of 5 June 2025, the technical trend for Theriva Biologics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish daily moving average and bearish signals from the weekly Bollinger Bands. However, there are mildly bullish indicators on the weekly MACD and KST, along with a bullish monthly RSI and OBV. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -76.39% versus the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-5.33%
EBIT to Interest (avg)
-17.89
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.51
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
28.16%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.25
EV to EBIT
0.22
EV to EBITDA
0.22
EV to Capital Employed
-0.53
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-114.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (1.02%)

Foreign Institutions

Held by 5 Foreign Institutions (0.64%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -57.83% vs -62.75% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-4.40",
          "chgp": "9.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.20",
          "val2": "-4.10",
          "chgp": "-124.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.10",
          "val2": "-8.30",
          "chgp": "-57.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.44% vs 8.50% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.60",
          "val2": "-22.00",
          "chgp": "15.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.60",
          "val2": "0.70",
          "chgp": "-1,185.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-25.70",
          "val2": "-18.30",
          "chgp": "-40.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.00
-4.40
9.09%
Interest
0.00
0.00
Exceptional Items
-9.20
-4.10
-124.39%
Consolidate Net Profit
-13.10
-8.30
-57.83%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -57.83% vs -62.75% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-18.60
-22.00
15.45%
Interest
0.00
0.00
Exceptional Items
-7.60
0.70
-1,185.71%
Consolidate Net Profit
-25.70
-18.30
-40.44%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -40.44% vs 8.50% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Theriva Biologics, Inc. stock-summary
stock-summary
Theriva Biologics, Inc.
Pharmaceuticals & Biotechnology
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics designed to treat gastrointestinal (GI) diseases. The Company's lead product candidates in Phase III development are SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and Phase II SYN-010 which reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company also develops SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
Company Coordinates stock-summary
Company Details
9605 Medical Center Dr Ste 270 , ROCKVILLE MD : 20850-6382
stock-summary
Tel: 1 734 3327800
stock-summary
https://www.syntheticbiologics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."